Mesoblast (US:MESO) Globenewswire·2026-03-11 23:21Core Insights - Mesoblast Limited has appointed Teresa Montagut MD, PhD as the Head of Clinical Development and Medical Affairs, a newly established position aimed at enhancing clinical collaborations and advancing cell therapy programs for inflammatory diseases [1][4] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing a proprietary mesenchymal lineage cell therapy technology platform [5] - The company’s lead product, Ryoncil® (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [6] Leadership and Expertise - Teresa Montagut brings extensive experience in medical leadership and pharmaceutical development, having previously held significant roles at Regeneron and other major pharmaceutical companies [2][3] - Her expertise in executing investigator-initiated clinical trials is expected to be crucial for expanding the indications of Ryoncil® and advancing Mesoblast's pipeline of cellular therapies [4] Product Development and Pipeline - Mesoblast is committed to developing additional cell therapies for various indications, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, as well as rexlemestrocel-L for heart failure and chronic low back pain [7] - The company has established commercial partnerships in key markets including Japan, Europe, and China [7] Intellectual Property and Manufacturing - Mesoblast holds a strong global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection until at least 2044 in major markets [8] - The company’s proprietary manufacturing processes enable the production of industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [9]